EUR/USD 1.08006
0.141%
Gold 2904.99
-0.199%
Oil 66.245
0.342%
USD/JPY 147.540
-0.296%
GBP/USD 1.28857
0.038%
GBP/JPY 190.119
-0.216%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
On March 7, Goldman Sachs published a research report stating that JD Health (06618.HK)s revenue growth in the second half of last year was in line with expectations, but the adjusted operating profit was lower than forecast. Net profit has also improved due to rising interest or other income. The report mentioned that JD Health managements profit guidance for 2025 is quite conservative, with sales expected to grow by double digits year-on-year and operating profit to remain flat year-on-year, as the company will focus on investing more in offline on-demand delivery and artificial intelligence initiatives in first-tier cities. Operating profit may decline year-on-year due to reduced interest income. In the long run, management is confident in further expanding its share and competitiveness in the online or offline pharmacy market.On March 7, Wang Yi said that we welcome all sectors of the two countries to strengthen exchanges, deepen mutually beneficial cooperation, and improve national sentiments, which are in line with the long-term interests of both sides. Regarding some specific concerns of the Japanese side, China will uphold a responsible attitude and properly handle them in accordance with laws and regulations.SpaceX will conduct a thorough investigation into the explosion and disintegration of the Starships second-stage spacecraft and cooperate with the Federal Aviation Administration (FAA).Hong Kong-listed pharmaceutical stocks strengthened, with Everest Medicines (01952.HK) rising more than 14%, EMTECH (02160.HK) rising more than 8%, and Fosun Pharma (02137.HK) rising 7.4%.Hong Kong stocks rose, the Hang Seng Tech Index turned positive, and the Hang Seng Index narrowed its decline to 0.29%. It had previously fallen by more than 1%.

The AUD/JPY Recovers from the Day's Low of 91.30, as the BOJ's Policy is Examined

Daniel Rogers

Apr 28, 2022 10:04

The AUD/JPY pair has drawn offers near 91.60 in the early Tokyo session, as investors await the Bank of Japan's (BOJ) monetary policy decision on Thursday. Since Wednesday, the pair has been swinging within a narrow range of 91.02-91.98 due to market participants' concern regarding the release of the BOJ's interest rate decision.

 

According to market expectations, the BOJ will maintain the status quo by maintaining current interest rates. Japan's inflation rate, at 1.2 percent, is the highest since October 2018 but remains much lower than the aim of 2%. Additionally, Japan's growth rate has not yet returned to pre-pandemic levels, implying that a rate hike decision is ruled out. Thus, an ultra-loose monetary policy will continue to be critical, and additional stimulus packages may be offered.

 

Meanwhile, the odds of the Reserve Bank of Australia (RBA) hiking rates have increased, mostly as a result of the Australian Bureau of Statistics reporting annual Australian inflation at 5.1 percent. Consumer Price Index (CPI) reading came in significantly higher than the forecasted 4.6 percent. Additionally, the quarterly CPI came in at 2.1 percent, exceeding expectations of 1.7 percent. The RBA stated at its most recent monetary policy meeting that they are not seeing any meaningful price pressure that would require them to announce a rate hike, and have adopted a data-dependent strategy for additional guidance. Now, the tide may be turning in May in favor of aggressive monetary policy.

AUD/JPY

 image.png


Suggestion